BIOMARIN PHARMACEUTICAL INC Interest on Convertible Debt, Net of Tax
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Interest on Convertible Debt, Net of Tax of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:InterestOnConvertibleDebtNetOfTax · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC interest on convertible debt, net of tax for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC interest on convertible debt, net of tax for the quarter ending 2026-03-31 was $1.83M, a 0.05% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC interest on convertible debt, net of tax for the quarter ending 2025-12-31 was $1.83M, a 0.16% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC interest on convertible debt, net of tax for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC interest on convertible debt, net of tax for fiscal 2025 was $7.33M, a 0.10% increase from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC interest on convertible debt, net of tax for fiscal 2024 was $7.33M.
- BIOMARIN PHARMACEUTICAL INC interest on convertible debt, net of tax for fiscal 2023 was $0.00.
- BIOMARIN PHARMACEUTICAL INC interest on convertible debt, net of tax for fiscal 2022 was $0.00.
| Period end | Interest on Convertible Debt, Net of Tax 3 month | Interest on Convertible Debt, Net of Tax 6 month | Interest on Convertible Debt, Net of Tax 9 month | Interest on Convertible Debt, Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $3.67M derived: sum of 3 quarters · filed 2026-08-06 | $3.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.83M 10-Q · filed 2026-05-05 | $3.67M derived: sum of 2 quarters · filed 2026-05-05 | $3.67M derived: sum of 3 quarters · filed 2026-05-05 | $5.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.83M derived: sum of 2 quarters · filed 2026-02-26 | $3.67M derived: sum of 3 quarters · filed 2026-08-06 | $7.33M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-28 | $1.83M derived: sum of 2 quarters · filed 2026-08-06 | $5.50M 10-Q · filed 2025-10-28 | $5.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.83M 10-Q · filed 2026-08-06 | $3.67M 10-Q · filed 2026-08-06 | $5.50M derived: sum of 3 quarters · filed 2026-08-06 | $7.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.83M 10-Q · filed 2026-05-05 | $3.67M derived: sum of 2 quarters · filed 2026-05-05 | $5.50M derived: sum of 3 quarters · filed 2026-05-05 | $8.27M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.66M derived: sum of 2 quarters · filed 2026-02-26 | $6.43M derived: sum of 3 quarters · filed 2026-02-26 | $7.33M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.83M 10-Q · filed 2025-10-28 | $4.60M derived: sum of 2 quarters · filed 2025-10-28 | $5.50M 10-Q · filed 2025-10-28 | $4.56M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.77M 10-Q · filed 2025-08-05 | $5.54M 10-Q · filed 2025-08-05 | $2.73M derived: sum of 3 quarters · filed 2026-02-26 | $2.73M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.77M 10-Q · filed 2025-05-02 | -$41.00K derived: sum of 2 quarters · filed 2026-02-26 | -$41.00K derived: sum of 3 quarters · filed 2026-02-26 | $896.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.81M derived: sum of 2 quarters · filed 2026-02-26 | -$1.87M derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 10-Q · filed 2024-10-31 | $937.00K derived: sum of 2 quarters · filed 2024-10-31 | $2.81M 10-Q · filed 2024-10-31 | -$932.00K derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-06-30 | $937.00K 10-Q · filed 2024-08-05 | $1.87M 10-Q · filed 2024-08-05 | -$932.00K derived: sum of 3 quarters · filed 2025-02-24 | -$932.00K derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-03-31 | $937.00K 10-Q · filed 2024-04-26 | -$1.87M derived: sum of 2 quarters · filed 2025-02-24 | -$1.87M derived: sum of 3 quarters · filed 2025-02-24 | -$1.87M derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-12-31 | -$2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$2.81M derived: sum of 2 quarters · filed 2025-02-24 | -$2.81M derived: sum of 3 quarters · filed 2025-02-24 | $0.00 10-K · filed 2025-02-24 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $2.81M 10-Q · filed 2023-11-02 | $2.76M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-02 | $1.87M 10-Q · filed 2023-08-02 | $2.76M derived: sum of 3 quarters · filed 2023-08-02 | $2.76M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $2.76M 10-Q · filed 2023-04-28 | $2.76M derived: sum of 2 quarters · filed 2023-04-28 | $2.76M derived: sum of 3 quarters · filed 2023-04-28 | $2.76M derived: sum of 4 quarters · filed 2023-04-28 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | $0.00 10-K · filed 2023-02-27 |
| 2021-09-30 | $0.00 10-Q · filed 2022-10-28 | $0.00 derived: sum of 2 quarters · filed 2022-10-28 | $0.00 10-Q · filed 2022-10-28 | -$10.02M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | -$10.02M derived: sum of 3 quarters · filed 2023-02-27 | -$2.95M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $0.00 10-Q · filed 2022-04-29 | -$10.02M derived: sum of 2 quarters · filed 2023-02-27 | -$2.95M derived: sum of 3 quarters · filed 2023-02-27 | |
| 2020-12-31 | -$10.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$2.95M derived: sum of 2 quarters · filed 2023-02-27 | $8.31M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $7.07M 10-Q · filed 2021-10-29 | $18.33M 10-Q · filed 2021-10-29 | ||
| 2020-03-31 | $936.00K 10-Q · filed 2021-04-30 | $936.00K derived: sum of 2 quarters · filed 2022-02-25 | $1.87M derived: sum of 3 quarters · filed 2022-02-25 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $937.00K derived: sum of 2 quarters · filed 2022-02-25 | $0.00 10-K · filed 2022-02-25 | |
| 2019-09-30 | $937.00K 10-Q · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | ||
| 2018-12-31 | $0.00 10-K · filed 2021-02-26 | |||
| 2014-09-30 | $156.00K 10-Q · filed 2015-11-02 | $0.00 10-Q · filed 2014-10-28 | ||
| 2013-09-30 | $0.00 10-Q · filed 2014-10-28 | $0.00 10-Q · filed 2014-10-28 | ||
| 2012-12-31 | $0.00 10-K · filed 2013-02-26 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $0.00 derived: sum of 2 quarters · filed 2013-02-26 | $0.00 10-K · filed 2013-02-26 | |
| 2011-09-30 | $0.00 10-Q · filed 2011-10-31 | $0.00 10-Q · filed 2011-10-31 | ||
| 2010-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $4.78M derived: sum of 2 quarters · filed 2013-02-26 | $9.98M 10-K · filed 2013-02-26 | |
| 2010-09-30 | $2.60M 10-Q · filed 2011-10-31 | $7.80M 10-Q · filed 2011-10-31 | ||
| 2009-12-31 | $0.00 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |